Dionne-OdomJ, TitaAT, SilvermanNS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol, 2016; 214:6–14.
2.
EhrhardtS, XieC, GuoN, et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence. Clin Infect Dis, 2015; 60:275–278.
3.
RosenthalP. Editorial commentary: The conundrum of lamivudine and tenofovir disoproxil fumarate for hepatitis B: Fetus versus infant. Clin Infect Dis, 2015; 60:279–280.
4.
VisvanathanK, DusheikoG, GilesM, et al.Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: Position paper produced by Australian, UK and New Zealand key opinion leaders. Gut, 2016; 65:340–350.
CottrellEB, ChouR, WassonN, et al.Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med, 2013; 158:109–113.
PfaenderS, HeydenJ, FrieslandM, et al.Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis, 2013; 208:1943–1952.
9.
TovoPA, CalitriC, ScolfaroC, et al.Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression. World J Gastroenterol, 2016; 22:1382–1392.
10.
SperaAM, EldinTK, TosoneG, et al.Antiviral therapy for hepatitis C: Has anything changed for pregnant/lactating women?. World J Hepatol, 2016; 8:557–565.
11.
AndersonGD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol, 2006; 2:947–960.
